July 15, 2016
TD2’s VP of Nonclinical Operations, Paul Gonzales, will be presenting at the upcoming 4th Annual Tumor Models – Boston (www.tumor-models.com) on Wednesday, July 20th. The topic of the presentation is The Role of the Gut Microbiome on the Anti-Tumor Response of Immune Checkpoint Inhibitors in a Syngeneic Murine Model of HPV-Associated Cancer.
Contact us if you’re interested in a copy of the presentation.
The FDA’s newly announced Plausible Mechanism Framework marks an important step toward aligning regulatory pathways with the realities of modern ...
Your browser does not support the video tag.
Your browser does not support the video tag. Receptor mediated therapies have fundamentally changed how cancer is treated in the clinic. What began ...
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
© 2026 Translational Drug Development. All Rights Reserved. Terms and Conditions | Privacy Policy
